

25 May 2022

ASX Announcement

Nasodine Patent Granted in Malaysia

- Firebrick's core patent covering Nasodine® Nasal Spray is now granted in 26 countries

Firebrick Pharma Limited (ASX:FRE) (Company or Firebrick) is pleased to announce that its patent covering Nasodine® Nasal Spray ("Nasodine") as a treatment and preventative for the common cold has now been granted in Malaysia.

This brings the number of countries where Firebrick's common cold patent has been granted to 26, including:

Australia	Great Britain	Portugal
Austria	Greece	Sweden
Belgium	Hong Kong	Turkey
Switzerland	Hungary	Malaysia
Germany	Ireland	New Zealand
Denmark	Italy	Philippines
Spain	Netherlands	South Africa
Finland	Norway	United States
France	Poland	

The patent is still pending in Canada, China, Japan and Singapore.

The patent, which expires in most countries in 2035, is titled: "*Treatment and prevention of the common cold using povidone-iodine*," and protects the intranasal use of povidone-iodine (in any form) for the treatment or prevention of the common cold.

Granted claims include treating and preventing colds, as well as reducing the viral load of common cold viruses, prevention of secondary complications of colds, such as bronchitis, otitis media and sinusitis, and reducing the risk of more serious complications in at-risk populations, such as those with COPD, asthma, emphysema cystic fibrosis, or compromised immunity.

"Establishing strong patent protection for Nasodine has been essential to the product's success, so it is truly gratifying to see the patent now granted in virtually all major markets," said Firebrick Executive Chairman, Dr Peter Molloy. "If Nasodine is launched in the near term, it would come to market with more than 10 years of commercial patent protection, which is an uncommonly valuable achievement in the pharmaceutical industry."

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold. The Company also owns a patent family that covers the use of intranasal povidone-iodine for the prevention of pandemic viral diseases, including COVID-19. Firebrick is currently undertaking two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com